Cardiopulmonary consumables revenue grew in the “mid-teens,” which Makatsaria attributed to market share gains, procedure growth, and price. He noted that oxygenator demand continues to outpace industry supply, though improvements in third-party component availability have enabled LivaNova to increase manufacturing output.In cardiopulmonary, revenue was $209 million, an increase of 14% versus the first quarter of 2025. Makatsaria said heart-lung machine (HLM) revenue grew in the “high teens,” driven by incr ...